Strong first-day trading momentum for Braveheart Bio (BRVE) underpins the 99.5% implied probability that its IPO closing market capitalization exceeds $1.6 billion. Shares priced at $18 in the upsized $382.5 million offering surged to close near $29.80–$30.20 on August 6, 2026, implying a market value above $2.1 billion based on post-offering shares outstanding—well above the $1.1–1.2 billion pre-IPO targets. This performance reflects robust institutional demand for the clinical-stage cardiovascular biotech’s lead myosin inhibitor in hypertrophic cardiomyopathy amid favorable biotech IPO sentiment. The offering is scheduled to close on August 7, leaving limited time for material reversals, though a sharp intraday pullback or unexpected share dilution could theoretically pressure the outcome below the threshold.
Eksperymentalne podsumowanie AI odwołujące się do danych Polymarket. To nie jest porada handlowa i nie ma wpływu na rozstrzyganie tego rynku. · Zaktualizowano$1.6B+ 99.5%
$1.45B-$1.6B <1%
<$1B <1%
$1B-$1.15B <1%
$3,821 Wol.
$3,821 Wol.
Aug 6, 2026
<$1B
No
$1B-$1.15B
No
$1.15B-$1.3B
No
$1.3B-$1.45B
No
$1.45B-$1.6B
No
$1.6B+
Yes
No IPO before October 2026
No
$1.6B+ 99.5%
$1.45B-$1.6B <1%
<$1B <1%
$1B-$1.15B <1%
$3,821 Wol.
$3,821 Wol.
Aug 6, 2026
<$1B
$260 Wol.
No
$1B-$1.15B
$526 Wol.
No
$1.15B-$1.3B
$579 Wol.
No
$1.3B-$1.45B
$981 Wol.
No
$1.45B-$1.6B
$547 Wol.
No
$1.6B+
$462 Wol.
Yes
No IPO before October 2026
$466 Wol.
No
This market will resolve based on Braveheart Bio's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on August 6 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Strong first-day trading momentum for Braveheart Bio (BRVE) underpins the 99.5% implied probability that its IPO closing market capitalization exceeds $1.6 billion. Shares priced at $18 in the upsized $382.5 million offering surged to close near $29.80–$30.20 on August 6, 2026, implying a market value above $2.1 billion based on post-offering shares outstanding—well above the $1.1–1.2 billion pre-IPO targets. This performance reflects robust institutional demand for the clinical-stage cardiovascular biotech’s lead myosin inhibitor in hypertrophic cardiomyopathy amid favorable biotech IPO sentiment. The offering is scheduled to close on August 7, leaving limited time for material reversals, though a sharp intraday pullback or unexpected share dilution could theoretically pressure the outcome below the threshold.
This market will resolve based on Braveheart Bio's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on August 6 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on August 6 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
Rynek otwarty: Aug 5, 2026, 5:48 AM ET
Wolumen
$3,821Data zakończenia
Aug 6, 2026Rynek otwarty
Aug 5, 2026, 5:48 AM ETResolver
0x69c47De9D...Wynik zaproponowany: No
Brak sporu
Ostateczny wynik: No
This market will resolve based on Braveheart Bio's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on August 6 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Strong first-day trading momentum for Braveheart Bio (BRVE) underpins the 99.5% implied probability that its IPO closing market capitalization exceeds $1.6 billion. Shares priced at $18 in the upsized $382.5 million offering surged to close near $29.80–$30.20 on August 6, 2026, implying a market value above $2.1 billion based on post-offering shares outstanding—well above the $1.1–1.2 billion pre-IPO targets. This performance reflects robust institutional demand for the clinical-stage cardiovascular biotech’s lead myosin inhibitor in hypertrophic cardiomyopathy amid favorable biotech IPO sentiment. The offering is scheduled to close on August 7, leaving limited time for material reversals, though a sharp intraday pullback or unexpected share dilution could theoretically pressure the outcome below the threshold.
This market will resolve based on Braveheart Bio's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on August 6 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on August 6 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
Wolumen
$3,821Data zakończenia
Aug 6, 2026Rynek otwarty
Aug 5, 2026, 5:48 AM ETResolver
0x69c47De9D...Wynik zaproponowany: No
Brak sporu
Ostateczny wynik: No
Strong first-day trading momentum for Braveheart Bio (BRVE) underpins the 99.5% implied probability that its IPO closing market capitalization exceeds $1.6 billion. Shares priced at $18 in the upsized $382.5 million offering surged to close near $29.80–$30.20 on August 6, 2026, implying a market value above $2.1 billion based on post-offering shares outstanding—well above the $1.1–1.2 billion pre-IPO targets. This performance reflects robust institutional demand for the clinical-stage cardiovascular biotech’s lead myosin inhibitor in hypertrophic cardiomyopathy amid favorable biotech IPO sentiment. The offering is scheduled to close on August 7, leaving limited time for material reversals, though a sharp intraday pullback or unexpected share dilution could theoretically pressure the outcome below the threshold.
Eksperymentalne podsumowanie AI odwołujące się do danych Polymarket. To nie jest porada handlowa i nie ma wpływu na rozstrzyganie tego rynku. · Zaktualizowano
Uważaj na linki zewnętrzne.
Uważaj na linki zewnętrzne.
Często zadawane pytania